KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
12.77
-0.28 (-2.15%)
At close: Aug 6, 2025, 4:00 PM
12.80
+0.03 (0.23%)
After-hours: Aug 6, 2025, 5:39 PM EDT
Verve Therapeutics Employees
KalVista Pharmaceuticals had 270 employees as of April 30, 2025. The number of employees increased by 120 or 80.00% compared to the previous year.
Employees
270
Change (1Y)
120
Growth (1Y)
80.00%
Revenue / Employee
n/a
Profits / Employee
-$679,422
Market Cap
635.46M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Apr 30, 2025 | 270 | 120 | 80.00% |
Apr 30, 2024 | 150 | 32 | 27.12% |
Apr 30, 2023 | 118 | 13 | 12.38% |
Apr 30, 2022 | 105 | 35 | 50.00% |
Apr 30, 2021 | 70 | 14 | 25.00% |
Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Apr 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Apr 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
KALV News
- 2 days ago - KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 12 days ago - KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks - Business Wire
- 22 days ago - KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema - Business Wire
- 27 days ago - KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results - Business Wire
- 4 weeks ago - KalVista: FDA Approval Of EKTERLY As Oral On-Demand HAE Drug Is Just Beginning - Seeking Alpha
- 4 weeks ago - US FDA approves KalVista Pharma's swelling disorder drug - Reuters
- 4 weeks ago - KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema - Business Wire
- 5 weeks ago - KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada - Business Wire